Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Chemoprevention and Biological Therapies

Abstract B109: Bioactivated chemotherapeutic agents based on ester-protected hydroxybenzyl phosphates (EHBP) for reversible alkylation of cellular nucleophiles

Ravinder Kodela, Steven Rokita, Daniel Boring, James Crowell and Khosrow Kashfi
Ravinder Kodela
City University of New York Medical School, New York, NY, University of Maryland, College Park, MD, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Rokita
City University of New York Medical School, New York, NY, University of Maryland, College Park, MD, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Boring
City University of New York Medical School, New York, NY, University of Maryland, College Park, MD, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Crowell
City University of New York Medical School, New York, NY, University of Maryland, College Park, MD, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khosrow Kashfi
City University of New York Medical School, New York, NY, University of Maryland, College Park, MD, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6207.PREV-08-B109 Published November 2008
  • Article
  • Info & Metrics
Loading
Abstracts: Frontiers in Cancer Prevention Research 2008

Abstract

B109

Introduction In cancer treatment, targeting the cellular DNA or its nucleotide precursors has been a viable method for inhibiting the synthesis of new genetic material or causing irreparable damage to the DNA itself. For example, agents such as bleomycins oxidatively degrade DNA, whereas cisplatin forms interstrand cross-links within DNA. Issues of selectivity and delivery remain a major problem in the development of new reactive agents. Typically, covalent reactions are irreversible, suppressing the potency of an agent. Reversible covalent reactions, in contrast, provide a strategy for recovering the reactive potential despite initial interaction with non-targeted constituents. Adding bioactivation to a reversible agent should ensure better selectivity and control for chemotherapy. Quinone methide precursors (QMP) are appropriate for this approach. Reactive and transient QMs and related electrophiles are formed during the metabolic activation of cytotoxic and genotoxic agents and may lead to DNA alkylation. Adducts formed between QMs and deoxyadenosine, deoxyguanosine, deoxycytosine, thymidine have been identified; reversible reaction dominates the initial product profile. We have elected to use dC which forms one reversible adduct to measure the relative reversibility of QM reaction vs bioactivity. We synthesized a series of EHBPs and determined the time-dependent evolution of their dC adduct.

Methods QMP: para-series, (agent 1) 4-acetyloxybenzyl diethylphosphate; (agent 2) 3,5-dimethyl-4-acetyloxybenzyl diethylphosphate; meta-series, (agent 3) 3-acetyloxybenzyl diethylphosphate; (agent 4) 2-chloro-3-acetyloxybenzyl diethylphosphate were synthesized, purified, and NMR verified. Adduct analysis: reverse phase-HPLC, unsubstituted and substituted QMPs were incubated ± esterase at 37 °C over 0.5 - 120 h.

Results Retention times for dC, internal standard, and all putative QMPs were first determined. Agent 1: Time course hydrolysis by the esterase was essentially complete in 4 hr, resulting in formation of dC and water adducts. The dC adduct formation was maximum at 6 h, thereafter slowly decomposing, with a half-life of approx. 21 h. Time course for formation of the water adduct showed that the product yield remained constant for 6-8 hrs indicating a stable product. These results are consistent with a rate determining hydrolysis of carboxylic ester group by the esterase giving a phenol that in turn rapidly undergoes a 1,6-elimination reaction to a QM. This then reacts with water and dC competitively to produce the identified adducts. Agent 2: Esterase reaction gave similar products to agent 1. However, the half-life for the decomposition of the dC adduct was significantly less (about 10 h) underscoring the effect of the electron releasing groups. Agent 3: Esterase hydrolysis yielded the phenol derivative which underwent so benzylic substitution with water yielding the corresponding benzyl alcohol, dC-N3 adduct did not form. Agent 4: Similar results to Agent 3, but the hydrolysis appeared to be much faster and incomplete.

Conclusions dC adduct formation was reversible, electron donating/withdrawing groups significantly affect the rate of adduct formation/decomposition. The meta analog did not form a QM. These results underscore the potential use of EHBPs as chemotherapeutic agents.

Citation Information: Cancer Prev Res 2008;1(7 Suppl):B109.

  • American Association for Cancer Research
Previous
Back to top
November 2008
Volume 1, Issue 7 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract B109: Bioactivated chemotherapeutic agents based on ester-protected hydroxybenzyl phosphates (EHBP) for reversible alkylation of cellular nucleophiles
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract B109: Bioactivated chemotherapeutic agents based on ester-protected hydroxybenzyl phosphates (EHBP) for reversible alkylation of cellular nucleophiles
Ravinder Kodela, Steven Rokita, Daniel Boring, James Crowell and Khosrow Kashfi
Cancer Prev Res November 1 2008 (1) (7 Supplement) B109; DOI: 10.1158/1940-6207.PREV-08-B109

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract B109: Bioactivated chemotherapeutic agents based on ester-protected hydroxybenzyl phosphates (EHBP) for reversible alkylation of cellular nucleophiles
Ravinder Kodela, Steven Rokita, Daniel Boring, James Crowell and Khosrow Kashfi
Cancer Prev Res November 1 2008 (1) (7 Supplement) B109; DOI: 10.1158/1940-6207.PREV-08-B109
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Chemoprevention and Biological Therapies

  • Abstract PR03: Targeting multiple cell cycle regulatory points for the prevention of triple-negative breast cancer
  • Abstract PR05: Low dose aspirin that reduces mortality from lung adenocarcinoma inhibits both platelet COX-1 and the biosynthesis of PGE2
  • Abstract PR13: Circadian/melatonin disruption by dim light at night drive chemotherapy resistance in breast cancer
Show more Chemoprevention and Biological Therapies

Poster Presentations - Proffered Abstracts

  • Abstract PR03: Targeting multiple cell cycle regulatory points for the prevention of triple-negative breast cancer
  • Abstract PR05: Low dose aspirin that reduces mortality from lung adenocarcinoma inhibits both platelet COX-1 and the biosynthesis of PGE2
  • Abstract PR13: Circadian/melatonin disruption by dim light at night drive chemotherapy resistance in breast cancer
Show more Poster Presentations - Proffered Abstracts

New Molecular Targets/Mechanisms of Drug Action

  • Abstract PR-01: Properties of adenomas in subjects treated with difluoromethylornithine and sulindac for reduction of colorectal adenomas
  • Abstract B85: Role of the TASK2 in regulating breast cancer cell proliferation
  • Abstract B106: Inhibition of IKKb and NFκB signaling by a novel curcumin analogue
Show more New Molecular Targets/Mechanisms of Drug Action
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement